Treatment of Chronic Myeloid Leukemia Cells with Imatinib (STI571) Impairs p53 Accumulation in Response to DNA Damage

Authors:
  • YLYaara Levav
    Yaara Levav
  • SKSvetlana Krichevsky
    Svetlana Krichevsky
  • EFEitan Fibach
    Eitan Fibach

Abstract
Chronic myelogenous leukaemia (CML) is induced by the Bcr-Abl fusion protein. Inhibition of Bcr-Abl by STI571 is widely used to treat CML patients. Unlike in most cancer types, the frequency of p53...